Han Biomedical

Han Biomedical ROIC

The Return on Invested Capital (ROIC) of Han Biomedical (6999.TWO) as of Nov 2, 2026 is 9.66 %. In the previous year, Return on Invested Capital (ROIC) was 10.12 % — a change of -4.49% (lower).

ROIC

9.66 %

YoY

-4.49%

Last updated:

Return on Invested Capital (ROIC) of Han Biomedical is 2024 9.66 % . Return on Invested Capital (ROIC) of Han Biomedical was 2023 10.12 % . It decreases by -4.49% lower compared to the previous year.

The Han Biomedical ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2022
9.58 TWD
Jan 1, 2023
10.12 TWD
Jan 1, 2024
9.66 TWD
The Han Biomedical ROIC history
YEARROICYoY
9.66 %-4.49%
10.12 %+5.63%
9.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Han Biomedical Stock analysis

What does Han Biomedical do? Han Biomedical Inc generates revenue through the design, development, and production of medical materials for tissue reconstruction and repair. Its primary products are BarriGel, a post-surgical anti-adhesion solution that prevents complications by extending degradation time, and Hancare, a collagen scaffolding material made from medical-grade collagen that adheres to wounds and absorbs exudate. The company distributes these products mainly within Taiwan's domestic market, targeting healthcare providers and medical facilities that require advanced tissue repair solutions. The firm focuses on natural biomedical materials, emphasizing product innovation for post-surgical care. BarriGel and Hancare are positioned as specialized medical solutions for wound management and adhesion prevention, catering to hospitals and clinics seeking effective tissue repair technologies. Revenue streams are derived from direct sales of these branded products to domestic healthcare institutions without external distribution channels. Han Biomedical Inc's business model centers on proprietary medical materials developed for specific clinical applications. The company's product portfolio includes BarriGel and Hancare, both designed to address post-surgical challenges with natural materials. Domestic market distribution ensures consistent revenue from local healthcare providers who prioritize advanced tissue repair solutions. Han Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Han Biomedical stock

Return on Invested Capital (ROIC) of Han Biomedical is 9.66 % in 2024.

Return on Invested Capital (ROIC) of Han Biomedical changed from 10.12 % to 9.66 %, representing a -4.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Han Biomedical since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Han Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Han Biomedical

All Key Metrics — Han Biomedical